Clinical and Molecular Characteristics of Myeloid Leukemia in Patients with Down Syndrome: Prognostic and Therapeutic Implications
DOI:
https://doi.org/10.56294/sctconf20231122Keywords:
Prognostic Implications, Myeloid Leukemia, GATA-1 Mutations, Molecular CharacteristicsAbstract
This study addresses the clinical and molecular characteristics of myeloid leukemia in patients with Down syndrome, a condition that presents unique challenges due to its complexity and heterogeneity. Through a multifaceted methodological approach, including a systematic literature review, a retrospective cohort study, genetic and molecular analysis, a prospective observational study, and the use of fuzzy cognitive maps, the prognostic and therapeutic implications of this condition were investigated. The results reveal distinctive features of myeloid leukemia in patients with Down syndrome, including a higher incidence, unique genetic profiles (especially GATA-1 mutations), and a differential response to treatments. The analysis identified the subtype of myeloid leukemia, initial response to treatment, and the presence of comorbidities as the most influential variables in the clinical course and prognosis. Personalized management strategies are proposed based on comprehensive genetic characterization, treatment adaptation according to the myeloid leukemia subtype, close monitoring of the initial response, and comprehensive management of comorbidities. These strategies, along with a multidisciplinary approach, show potential to improve clinical outcomes and patients' quality of life. The study provides a solid foundation for developing more effective and personalized treatment protocols, emphasizing the importance of a comprehensive approach that considers the genetic, clinical, and demographic particularities of this population. The need for additional research to validate and optimize these approaches in clinical practice is highlighted.
References
1. Kats DJ, Donelan K, Banerjee S, de Graaf G, Skladzien E, Hooper BT, et al. Results of inaugural international Down Syndrome Societal Services and Supports survey. Genet Med [Internet]. 2024;26(5):101114. Available from: https://www.sciencedirect.com/science/article/pii/S1098360024000479 DOI: https://doi.org/10.1016/j.gim.2024.101114
2. Huang J, Hu G, Suo P, Bai L, Cheng Y, Wang Y, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: A single-center study. Front Oncol. 2023;13:1116205. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1116205/full DOI: https://doi.org/10.3389/fonc.2023.1116205
3. Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022 Mar;171:103607. https://pubmed.ncbi.nlm.nih.gov/35101585/ DOI: https://doi.org/10.1016/j.critrevonc.2022.103607
4. Siddappaswamy H, Jayaraman D, Balakrishnan U, Koshy T, Scott JX. Transient myeloproliferative disorder in a neonate without down syndrome – A rare event and clinical dilemma. Pediatr Hematol Oncol J [Internet]. 2023;8(4, Supplement):S59. Available from: https://www.sciencedirect.com/science/article/pii/S2468124523002103 DOI: https://doi.org/10.1016/j.phoj.2023.10.150
5. López Hernández G, Olivas Román LR, del Pilar Salazar Rosales H, Corcuera Delgado CT. Lactante menor con leucemia congénita y enfermedad de injerto contra huésped postrasplante. Acta Pediátrica México. 2020;40(4):223–33. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=90503 DOI: https://doi.org/10.18233/APM40No4pp223-2331854
6. Mansini AP, Rubio PL, Rossi JG, Gallego MS, Medina A, Zubizarreta PA, et al. Caracterización de mutaciones en el gen GATA-1 en pacientes con Síndrome de Down y diagnóstico de mielopoyesis anormal transitoria o leucemia megacarioblástica aguda. Arch Argent Pediatr. 2013;111(6):0. http://www.scielo.org.ar/scielo.php?pid=S0325-00752013000600013&script=sci_arttext&tlng=en DOI: https://doi.org/10.5546/aap.2013.532
7. Díaz Hernández DJ, Torres Gómez IP, Arango Martínez AM, Manrique Hernández RD, Gallo Bonilla JE. Aspectos genómicos, transcriptómicos y del diagnóstico en el síndrome de Down. Med Lab. 2020;24(1):37–56. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=93441 DOI: https://doi.org/10.36384/01232576.13
8. Chen AR, Wang YM, Lin M, Kuo DJ. High-dose methotrexate in pediatric acute lymphoblastic leukemia: predictors of delayed clearance and the effect of increased hydration rate on methotrexate clearance. Cureus. 2020;12(6):e8674. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370657/ DOI: https://doi.org/10.7759/cureus.8674
9. Amador LG, Villacorta J, Peña A. Leucemia Congénita en Síndrome de Down. Rev MEDICA HONDURÑA. 1996;64(3):1–107. http://34.230.102.254/assets/Uploads/Vol64-3-1996-7.pdf
10. Palacio Lavid M, Jaramillo PE, Gálvez KM, Salazar E. Caracterización del síndrome mielodisplásico y su relación con el sistema internacional de puntuación pronóstica en una institución prestadora de servicios de salud de tercer nivel en Colombia. Rev Colomb Hematol y Oncol. 2023;(Supl):100. https://www.metarevistas.org/Record/f855918593b71ae38dff7093f83dd555/Similar DOI: https://doi.org/10.51643/22562915.580
11. Rodríguez Aguirre MI, Hernández Cuéllar E, Espinoza Román VH, Acevedo Segura VG, Lagos Córdova EY, Vera Morales CD, et al. Características clínicas y resultado del tratamiento de niños con leucemia linfoblástica aguda e hiperleucocitosis. Gac Mex Oncol. 2021;20:23–7. https://www.scielo.org.mx/scielo.php?pid=S2565-005X2021000500023&script=sci_arttext DOI: https://doi.org/10.24875/j.gamo.21000031
12. Corona Martínez LA, Fonseca Hernández M. Acerca del carácter retrospectivo o prospectivo en la investigación científica. Medisur. 2021;19(2):338–41. http://scielo.sld.cu/scielo.php?pid=S1727-897X2021000200338&script=sci_arttext
13. Infante-Moro A, Infante-Moro JC, Gallardo-Pérez J. Los mapas cognitivos difusos y su aplicación en la investigación de las ciencias sociales: estudio de sus principales problemáticas. Educ Knowl Soc. 2021;22(e26380):e26380–e26380. https://revistas.usal.es/tres/index.php/eks/article/view/26380 DOI: https://doi.org/10.14201/eks.26380
14. Castro MX. Trastornos mieloproliferativos y leucemia en síndrome de Down. Presentación de dos casos clínicos en el período neonatal. Arch Argent Pediatr. 2022;120(2):16. http://www.scielo.org.ar/scielo.php?pid=S0325-00752022000200016&script=sci_abstract&tlng=en DOI: https://doi.org/10.5546/aap.2022.e89
15. Kaindl U, Morak M, Portsmouth C, Mecklenbräuker A, Kauer M, Zeginigg M, et al. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia. 2014;28(3):600–8. https://www.nature.com/articles/leu2013345 DOI: https://doi.org/10.1038/leu.2013.345
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Olivia Elizabeth Altamirano Guerrero, Piedad Elizabeth Acurio Padilla, Juan Sebastián Lima Icaza (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
